LCFA presents lung cancer research grant opportunities to researchers worldwide who present the “best in science” projects in the field. These annual lung cancer research grant awards are 6-figure grants, allowing the researcher to set up a lab, hire personnel and begin to amass data to prove their hypotheses.
LCFA awards research grants to young investigators who present projects that will have the best impact on the lives of lung cancer patients.
More details
2022 Lung Cancer Foundation of America –
Bristol-Myers Squibb/ILCF
Young Investigator Disparities in Clinical Oncology
Research Fellowship
Funding Opportunity Description
Lung Cancer Foundation of America (LCFA), seeks applications for the LCFA Young Investigator Diversity and Inclusion in Clinical Oncology Research Fellowship.
Overview
LCFA is committed to advancing innovative lung cancer research with a focus on immunotherapy leading to transformative treatment protocols. In order to ensure success, we are casting the widest net possible in order to attract the most creative and originative young investigators and research institutions.
LCFA recognizes that not all Young Investigators are represented by the traditional “big comprehensive cancer research centers” which typically make up the NCI pipeline of funding. Accordingly, LCFA aims to fund Young Investigators who represent the diversity among institutions and investigators in lung cancer clinical research.
In order to achieve this, we encourage young investigators from diverse populations and under-represented institutions to apply. Recognizing the importance of diversity, equity and inclusion in the oncology and biomedical research workplace, promising investigators who have been shown to be underrepresented in academic medicine and/or in the field of lung cancer research, are encouraged to apply. We anticipate that these Applicants may be from racial and ethnic groups, and individuals with disabilities who have the skills, knowledge and resources necessary to carry out their proposed research.
Examples of potential research, though not exclusive, include studies designed to determine predictive features guiding the selection of patients for different immuno-oncology therapies; application of these therapies in combination with standard therapies, such as standard curative-intent strategies in early-stage disease; ways to improve the effectiveness of immuno-oncology therapies; or even cure patients with metastatic lung cancer. Studies designed to facilitate care by minimizing treatment side effects are encouraged as well.
Education and Experience
At the time of application, an applicant must hold a doctoral degree, (including PhD, MD, DO, PharmD, ScD or equivalent) have less than 7-years of postdoctoral experience, and be actively engaged in research, at an institution in the United States, evaluating the use of the immune system to improve the lives of patients with lung cancer.
Note: Applicants must be a member of the IASLC. Go to https://www.iaslc.org/membership to join or get more information about IASLC Membership.
Hear from Dr Triparna Sen talk about how LCFA’s Young Investigator Grant has helped her.
Dr. Triparna Sen, Associate Professor at Icahn School of Medicine at Mount Sinai, New York City, was the recipient of a 2020 LCFA/IASLC/BMS Young Investigator lung cancer research grant. Her research is looking at the immune system to target and eliminate small cell lung cancer, the most aggressive and metastatic form of lung cancer.
Past Lung Cancer Research Grant Awardees
To attract the best and the brightest to the field of lung cancer, LCFA is committed to supporting young investigators with significant grant funding to pursue a long-term project over the course of multiple years. Meet some of our past Award Recipients.
